The invention relates to a composition comprising a cell-free lipoaspirate-derived preparation comprising a lipid fraction and / or an aqueous fraction of a lipoaspirate and at least one biodegradable crosslinked hydrogel. The invention further relates to a device and a kit comprising the composition. The composition, the device and the kit can be generally applied for aesthetic treatment of soft-tissue loss or deficit.
Disclosed is a lipid nanoparticle (LNP) encapsulating a nucleic acid cargo preferably comprising messenger ribonucleic acid (mRNA) The LNP comprises at least a cationic lipid fraction, and a stabilizer fraction. The stabilizer fraction preferably comprises at least one polyethylenglycol (PEG) lipid. Furthermore, the LNP comprises at least one glycerol dialkyl glycerol tetraether (GDGT) lipid, as obtained e.g. from archaea of the genus Sulfolobus, optionally among other ether lipids. Also disclosed is a pharmaceutical composition comprising the LNP, such as an mRNA vaccine.
The invention relates to a composition comprising a cell-free lipoaspirate-derived preparation comprising a lipid fraction and / or an aqueous fraction of a lipoaspirate and at least one biodegradable crosslinked hydrogel. The invention further relates to a device and a kit comprising the composition. The composition, the device and the kit can be generally applied for aesthetic treatment of soft-tissue loss or deficit.